The global market for wound care in 2021 exceeds USD$16 billion , of which 2/3 are Advanced Wound Care products (growing rapidly due to causes such as diabetes epidemics). A significant and fastest growing part of the market is in developing nations in Asia, Africa and South America.
Diabetic foot ulcers are one of the most common and serious complications associated with diabetes mellitus and affect around 15% of patients with diabetes in their lifetime. A failure to heal can often lead to amputation. The diabetic condition impacts negatively on normal wound healing by affecting the microvasculature so that the wound is poorly vascularised. It also adversely affects normal innervation leading to the loss of peripheral sensory and autonomic nerves and the constant high glucose has an adverse effect on the immune system making the patient less able to counteract skin infections.
Cannenta has acquired exclusive rights to a patented unique sugar-based angiogenesis factor for accelerating wound recovery in patients.
The technology works by stimulating the patient production of vascular endothelial growth factor (VEGF) which is a protein that stimulates the formation of blood vessels, which in turn is the prerequisite to forming a viable wound bed for new skin formation.
The angiogenesis factor can be incorporated into a range of conventional wound dressings for convenient application to the patient.
Cannenta is preparing for clinical trials from 2021 for initial regulatory approval as a therapeutic product. The product range will be extended over time to cover additional indications for a variety of chronic or difficult to heal wounds.
The company works with healthcare providers and established distributors in the target markets.
Iain has a career spanning design and development, project management, general management, management consulting (business processes) and investment management in the engineering and advanced materials and biotechnology sectors. He has managed tech start-ups and served on the boards of Cytomatrix Ltd and Circa Group Ltd and is well placed to oversee the business operations and key relationships as the business grows. Has MBA (Tech Management) Deakin University and BE(Mech) University of Melbourne.
Xenia is a highly experienced senior healthcare executive with more than 30 years’ experience in senior regulatory, clinical, program management and international commercialisation roles. As a former senior executive of CSL, her experience includes the registration and launch of novel therapeutics, establishing subsidiaries in the USA and Europe, distributors ROW and setting up CSL’s global regulatory function. As Research and Business Manager, Epworth HealthCare, Xenia expanded the research business and managed the Clinical Research Unit. She is well placed to oversee the development activities for taking Cannenta’s product through to market.
Dr Muhammad Yar
Dr Yar serves in the Interdisciplinary Research Centre in Biomedical Materials (IRBCM), COMSATS University, Lahore, Pakistan as an Associate Professor of Biomaterials and Tissue Engineering. He is cluster head of the skin tissue engineering group and has published over 76 Journal papers and has 14 Patents (filed/issued) including one on sugar scaffolds to enhance angiogenesis (with Prof MacNeil), which is the technology licensed to Cannenta. He consults to medical devices companies and works with burn and plastic surgeons.
Prof Sheila MacNeil
Emeritus Professor of Tissue Engineering at Sheffield University, UK, with expertise in tissue engineering and translating research to the clinic. Has published 400+ articles with 8500+ citations. Since 1992, has delivered autologous keratinocytes to burns patients and developed and commercialised improved delivery of skin cells to patients with myskin™ and cryoskin™ (Regenerys). With Prof Yar has a joint patent in promoting neovascularisation when delivered from a variety of substrates both in vitro and in vivo.
Winthrop Prof Fiona Wood (AM)
A Plastic & Reconstructive Surgeon specialising in the field of burn care, trauma and scar reconstruction. Director of the WA Burns Service of Western Australia, consultant at Perth Children’s and Fiona Stanley Hospitals. Awards: 2003 AMA Contribution to Medicine Award; Order of Australia Medal for work with Bali bombing victims; 2005 Australian of the Year; 2005 Clunies Ross Award for contributions to Medical Science in Australia (with Marie Stoner as co-founder of Clinical Cell Culture, now Avita Medical, which developed a spray on skin device).
Dr P. Stuart Esnouf
Dr Esnouf trained in medicine and surgery. He has founded/co-founded many tech companies to commercialise medical devices he has designed (in Australia & Hong Kong). Has been instrumental in the trade sale of four of these companies to large multinationals at substantial returns on investment. Is the named inventor of 50+ patents and has consulted for venture capital firms and IPO underwriters on the appraisal of medical device technologies. Has MBBS from University of Melbourne.
Ajit has been involved in technology since 1992 and held management positions in Australia and the UK. He has worked with corporate and government businesses throughout his career and founded a successful ICT business in 2010. Has BEng (Honours) from London Metropolitan University.
Dr Eryadi Masli
Dr Masli (Simon) is advisor to the Ministry of Science and Technology’s NATEC (National Agency for Technology Entrepreneurship and Commercialization Development) in Vietnam. Dr Masli had been working as an equity analyst and investment banker for 12 years in the Southeast Asia region. He has taught at universities in Indonesia, Thailand and Australia. Has BA (Economics) and MBA (Finance) from SFSU, California USA and PhD (Entrepreneurship) from Swinburne University.
Dr Jerzy (George) Muchnicki
Monash University Medical school MBBS. Clinical medicine pracitioner: 1981-2004. Since then Georg has been involved as a VC focusing on R&D in Stem cells, Genetic engineering and Drug repurposing and actively involved as Executive Board member and Medical consultant at Genetic technologies (ASX: GTG, NASDAQ:GENE) Interim CEO at GTG ( ASX: GTG, NASDAQ:GENE) CMO at GTG ( ASX: GTG, NASDAQ:GENE)
Elmo de Alwis
Former pharmaceutical executive, finance and commercial roles. Ex Managing Director Sigma Pharmaceuticals – achieved the strongest growth in share price during one financial year and moved into the ASX Top 100 index. Elmo was awarded the 2006 Chartered Accountants Business Leader Award for the Service Sector and in July 2006 was voted the 2nd most Admired CEO of the ASX Listed Companies.
Former Investment Director – Information City Australia – Responsible for all aspects of investment lifecycle, from deal sourcing and execution through portfolio management, board representation and exit creation. Previously a corporate and tax lawyer and merchant banker in Australia and the UK; specializing in M&A, taxation and PE transactions. Mentor, Melbourne Accelerator Program since 2012. Co-Trustee, Foundation behind The Vernier Society